Lantheus Holdings (LNTH) Total Non-Current Liabilities (2013 - 2026)
Lantheus Holdings (LNTH) reported Total Non-Current Liabilities of $1.1 billion for Q1 2026, up 36.18% year-over-year from $832.8 million in Q1 2025, and little changed quarter-over-quarter from $1.1 billion in Q4 2025.
Lantheus Holdings (LNTH) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 14 years of Total Non-Current Liabilities data on file, last reported at $1.1 billion in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $1.1 billion, up 36.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 36.18% YoY), and the FY2025 annual result was $1.1 billion, up 37.18% from the prior year.
- Total Non-Current Liabilities held at $1.1 billion in Q1 2026 per LNTH's latest filing, from $1.1 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.1 billion in Q4 2025 and troughed at $395.8 million in Q1 2022.
- A 5-year average of $811.8 million and a median of $829.1 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 124.98% in 2022, then fell 4.61% in 2023.
- A 5-year view of Total Non-Current Liabilities shows it stood at $851.6 million in 2022, then fell by 4.61% to $812.3 million in 2023, then advanced by 2.07% to $829.1 million in 2024, then jumped by 37.18% to $1.1 billion in 2025, then retreated by 0.29% to $1.1 billion in 2026.
- Business Quant data shows LNTH's Total Non-Current Liabilities at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.13 Bn |
| Dec 31, 2025 | 1.14 Bn |
| Sep 30, 2025 | 1.04 Bn |
| Jun 30, 2025 | 949.16 Mn |
| Mar 31, 2025 | 832.84 Mn |
| Dec 31, 2024 | 829.15 Mn |
| Sep 30, 2024 | 807.93 Mn |
| Jun 30, 2024 | 888.05 Mn |
| Mar 31, 2024 | 822.69 Mn |
| Dec 31, 2023 | 812.34 Mn |
| Sep 30, 2023 | 820.35 Mn |
| Jun 30, 2023 | 762.35 Mn |
| Mar 31, 2023 | 857.56 Mn |
| Dec 31, 2022 | 851.57 Mn |
| Sep 30, 2022 | 434.53 Mn |
| Jun 30, 2022 | 424.30 Mn |
| Mar 31, 2022 | 395.80 Mn |
| Dec 31, 2021 | 378.51 Mn |
| Sep 30, 2021 | 258.83 Mn |
| Jun 30, 2021 | 334.87 Mn |